On Oct 13, Li Li, commissioner of the National Medical Products Administration (NMPA), met in Beijing with a delegation led by Minister of Health of Brazil Alexandre Padilha.

Li reviewed the history of cooperation between China and Brazil in drug regulation and gave an overview of China's drug regulatory work and the development of the pharmaceutical industry.

He pointed out that in recent years, China's NMPA has consistently prioritized ensuring drug quality and safety as its most fundamental responsibility. It continuously promoted the scientific, rule-based, international and modern development of drug regulation through measures such as improving regulatory system and standards, strengthening safety oversight, deepening reform, accelerating market approval of innovative drugs, advancing smart regulation, and deepening international cooperation, he added.

Padilha introduced Brazil's healthcare system development plans and related initiatives to promote the development of the pharmaceutical industry through drug approval reforms.

He expressed hope to improve people's well-being by promoting industrial innovation and said he looked forward to further expanding bilateral cooperation in the pharmaceutical fields to jointly advance sustainable development.

Both sides agreed to deepen the China-Brazil health cooperation mechanism, enhance collaboration in drug review and regulatory coordination, and promote exchanges and mutual learning between the pharmaceutical industries of the two countries, ensuring that more innovative medical achievements benefit the people of both countries.

Officials from relevant departments and affiliated institutions of the NMPA were also present.